Related Experiment Videos
Novel indications for BRCA1 screening using individual clinical and morphological features
F Eisinger1, C Noguès, J M Guinebretière
1Department of Genetic Oncology/INSERM CRI 9703, Paoli-Calmettes Institute, Marseille, France.
International Journal of Cancer
|June 17, 1999
Summary
BRCA1 gene mutation carriers can be identified by early cancer onset, estrogen-receptor negativity, and poor differentiation. This model improves BRCA1 screening accuracy, identifying a high-risk subgroup for genetic testing.
Area of Science:
- Oncology
- Genetics
- Biostatistics
Background:
- BRCA1 gene mutations are linked to hereditary breast and ovarian cancers.
- Identifying BRCA1 carriers is crucial for targeted treatment, but family history is often insufficient.
- Current screening methods may miss eligible candidates due to a lack of clear familial patterns.
Purpose of the Study:
- To develop a predictive model for identifying BRCA1-breast cancer (BRCA1-BC) cases.
- To discriminate between sporadic breast cancers and BRCA1-BCs using clinical and morphological parameters.
- To enhance BRCA1 screening strategies, especially when family history is unavailable.
Main Methods:
- Multivariate logistic-regression analysis was employed.
- Studied 32 BRCA1-BC cases and 200 controls, analyzing age at onset and tumor morphology.
- Validated the model using a hospital-based registry of 5700 breast cancer cases.
Main Results:
- Early age at onset (OR=1.16), estrogen-receptor negativity (OR=5.7), and poor differentiation (OR=5) significantly predicted BRCA1-carrier status.
- A model combining these factors improved mutation detection rates.
- In women with estrogen-receptor-negative and poorly differentiated tumors, the predicted BRCA1 mutation detection rate exceeded 10%.
Conclusions:
- A predictive model incorporating early onset, ER negativity, and poor differentiation enhances BRCA1 mutation detection.
- This model identifies a specific subgroup (approx. 1% of cases) with a high probability of BRCA1 mutation.
- Targeted genetic testing for this subgroup is recommended, aligning with ASCO guidelines.